

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|             |                                  |   |                   |                |
|-------------|----------------------------------|---|-------------------|----------------|
| Applicant:  | Mezher Hussein Ali <i>et al.</i> | ) | Examiner:         | Celia C. Chang |
|             |                                  | ) |                   |                |
| Serial No.: | 10/522,208                       | ) | Group Art Unit:   | 1625           |
|             |                                  | ) |                   |                |
| Filed:      | July 17, 2003                    | ) | Confirmation No.: | 3691           |
|             |                                  | ) |                   |                |
| Title:      | PIPERIDINETRIOL DERIVA-          | ) | Docket:           | AC-21-US       |
|             | TIVES AS INHIBITORS OF           | ) |                   |                |
|             | GLYCOSYCERAMID SYNTHASE)         | ) |                   |                |

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached SB/08 form be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the SB/08 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

The filing of this Information Disclosure Statement is not be construed as a representation that a search has been made, nor construed to be an admission that the information cited in this Information Disclosure Statement is, or is considered to be, material to patentability or prior art.

Pursuant to 37 C.F.R. §1.98(a), copies of references which are non US patents and patent applications are enclosed herein.


INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. If any other additional fees are presently required, or required during the pendency of this application (other than payment of the issue fee), please charge the same to Deposit Account 50-4255. If there are any questions relating to fee payments associated with this application, please contact the undersigned attorney at the contact information listed below.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,


Date 2/16/2010

By   
Brittany La  
Reg. No. 58,337

Hoxie & Associates LLC  
75 Main Street, Suite 301  
Millburn, New Jersey 07041  
973-912-5232  
973-912-5236 (fax)

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this \_\_\_\_ day of February, 2010.

  
Name

  
Signature